[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"circulating-tumor-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:circulating-tumor-cell":314},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,71,95,121,147,168,193,218,244,267,292],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100465885","liquid-biopsy-and-pancreas-cancer-detection-of-axl-ctcs-ctc-axl-panc-100465885",false,"NCT05346536","Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)","Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP","CTC-AXL-PANC","Inclusion Criteria:\n\n* The patient is at least 18 years old;\n* Patients with pancreatic cancer with remote metastases, naïve of any treatment, that is, eligible for a first line of treatment;\n* Patients with oral consent\n\nExclusion Criteria:\n\n* Non-affiliation or non-beneficiary of a Social Security regimen;\n* Frailty persons according to Article L1121-6 of the CSP;\n* Adult protected or unable to give consent as per Article L1121-8 of the CPMP;\n* Pregnant or lactating women as per MSC L1121-5.\n* Not included for monitoring difficulties (mutation, insufficient motivation, predictable poor compliance, priority associated pathology in care, etc.)","ALL","18 Years",{"count":20,"type":21},63,"ESTIMATED","INTERVENTIONAL",[24],"NA","In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases. These circulating tumor cells (CTCs) that have become disseminated tumor cells (DTCs) flourish in their new environments and may remain dormant for many years after the complete resection of the primary tumor. Detecting CTCs in the blood is also relevant for assessing tumor progression, prognosis and therapeutic follow-up. The non-invasive, highly sensitive for CTCs analysis is called \"liquid biopsy\". Pancreatic adenocarcinoma and breast cancer remain among cancers of very poor prognosis and thus represent a major therapeutic challenge. In recent years, the Axl membrane tyrosine kinase receptor has been the target of growing interest. Activation of the Gas6\u002FAxl signaling pathway is associated with, among other things, tumor cell growth and survival, epithelial to mesenchymal transition (EMT) or drug resistances. In addition, Axl overexpression is frequently identified in patients with pancreatic adenocarcinoma and is associated with a poor prognosis. For example, the Laboratoire des Cellules Circulantes Rares Humaines (LCCRH) at the CHU and the University of Montpellier has developed two new \"CTC-AXL\" tests to detect CTCs expressing Axl: one using the CellSearch® (gold standard and FDA-approved) system and the other using the EPIDROP technique. The purpose of this research project is to assess the concordance of the \"CTC-AXL\" measurement by the innovative EPIDROP technique and the CellSearch® technique in patients with metastatic pancreatic or breast cancer.",[27,28,29],"Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Cancer","Circulating Tumor Cell",[28,29,31,32],"AXL","CellSearch","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2022-06-16",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"University Hospital, Montpellier","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100466941","ctcs-in-breast-cancer-after-neoadjuvant-treatment-and-surgery-a-multicenter-prospective-clinical-trial-100466941","NCT05360290","CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial","The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial","CTCNeoBC-E","Inclusion Criteria:\n\n* Female, aged ≥18 and ≤70 years;\n* Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);\n* Completed neoadjuvant treamtment and surgery (within 4 years after surgery);\n* Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Female patients who are pregnancy or lactation;\n* Uncontrollable puncture site infection or systemic infection;","FEMALE","70 Years",{"count":57,"type":21},484,[24],"The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.",[61,29],"Breast Cancer","2026-02-01",{"date":64,"type":37},"2026-02-03",{"date":66,"type":37},"2022-09-14",{"date":68,"type":21},"2029-06",{"name":70,"class":44},"RenJi Hospital",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":45},"100404333","detecting-chemosensitivity-and-predicting-treatmemt-efficacy-with-ctcs-in-mnpc-100404333","NCT04544969","Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC","Detecting Chemosensitivity and Predicting Treatmemt Efficacy With Circulating Tumour Cells From Peripheral Blood in Metastatic Nasopharyngeal Carcinoma Patients","Inclusion Criteria:\n\n* NPC patients with distant metastasis after 3 months of primary radiotherapy, and not suitable for local treatment\n* At least having one measurable metastatic lesion\n* All genders，range from 18～70 years old\n* ECOG score 0 \\~ 1\n* Expected survival time ≥ 3 months\n* White blood cell(WBC) count ≥ 3×109\u002FL, neutrophile granulocyte(NE) count ≥ 1.5×109\u002FL, hemoglobin(HGB) ≥ 90g\u002FL, platelet(PLT) count ≥ 100×109\u002FL\n* Alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \\\u003C 2.5×upper limit of normal(ULN), bilirubin(BUN) or creatinine(CRE) \\\u003C 1.5×ULN, alanine aminotransferase (CCR) ≥ 60ml\u002Fmin\n* Inform consent form\n\nExclusion Criteria:\n\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension.",{"count":79,"type":21},50,"1 Year","OBSERVATIONAL","The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs dynamic change.",[29,84,85,86],"Nasopharyngeal Carcinoma","Distant Metastases.Clinical","Effects of Chemotherapy","2025-01-25",{"date":89,"type":37},"2025-01-28",{"date":91,"type":37},"2020-04-01",{"date":41,"type":21},{"name":94,"class":44},"Sun Yat-sen University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100574167","using-a-3d-culture-model-for-circulating-tumor-cells-combined-with-molecular-bioassays-in-patients-with-hnscc-cancer-100574167","NCT06755762","Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer","Using A Three-dimentional Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With Head and Neck Cancer to Help Determine the Precise Choice of Systemic Drugs to Improve Survival Outcomes","Inclusion Criteria:\n\n1. age ≥ 18\n2. agree with blood drawing and follow the procedure of the trial\n\na.health participants:without cancer over 5 yaers b.cancer participants:pathology: metastatic HNSCC patients\n\nExclusion Criteria:\n\n1. health participants:with serious illness\n2. cancer participants:none",true,"80 Years",{"count":105,"type":21},88,"Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly. Till now, the reasons why some cancer recurs and others do not remain unclear. Since 2004, circulating tumor cell (CTC) has been well-recognized that CTCs in the circulatory system are associated with cancer metastasis. The fundamental studies of CTCs hold tremendous potentials for probing the biological insights on the molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, or biomarker discovery. However, the low purity (one of the natural limitations) of isolated samples often hampered CTC-directed studies' utility. For that, investigators used a well-established device (ODEP, optically-induced-dielectrophoresis) to isolate viable and high-purity CTCs for the following investigations. Investigators team developed a protocol in the past months and succeeded in cultivating CTCs (near 100%) for further drug tests and had a technology platform of organoid culture system developing in 2020. The preliminary results of the experiments showed a promising combination. That urges investigators to propose a 3-year project investigating CTC culture in the organoid system to look at (1) the behavior of CTCs in organ cell background (organoid), (2) the influences of different background cells, (3) the different in-vitro (or in-organoid) response of CTCs to specific drugs (pembrolizumab, nivolumab, cetuximab, cisplatin, 5-FU, taxanes) of head and neck squamous cell carcinoma. In the meantime, investigators will look at the genomic alterations of those CTCs growing fast and well in the organoid systems to find possible precipitating metastasis genes at a scale of cell (CTC) level. Investigators believe that the project is doable and possibly help human cancer control and understanding.",[29,108],"HNSCC",[110,111,108],"circulating tumor cell","organoid","2024-12-30",{"date":114,"type":37},"2025-01-01",{"date":116,"type":37},"2024-08-01",{"date":118,"type":21},"2027-07-31",{"name":120,"class":44},"Chang Gung Memorial Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100558897","early-phase-1-csf-ctc-capture-guided-egfr-tki-and-bevacizumab-combination-therapy-in-egfr-mutant-advanced-nsclc-100558897","NCT06557096","CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC","Open-label, Single-Arm, Multicenter Clinical Study of EGFR-TKIs Sequentially Combined With Bevacizumab for the Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer, Based on Early Warning by CSF CTC Capture Technology","Inclusion Criteria:\n\n* 1.The subjects voluntarily joined this study and signed the informed consent form, showing good compliance and cooperation with follow-up.\n\n  2.Ages between 18 years old (inclusive) and 75 years old (inclusive). 3.ECOG score: 0-2 points. 4.Expected survival of no less than 3 months. 5.According to the RECIST 1.1 criteria, the patient has at least one extracranial target lesion.\n\n  6.Diagnosed with non-small cell lung cancer based on histology or cytology. 7.No leptomeningeal metastasis (EANO criteria). 8.The tumor tissue samples or blood samples are confirmed to have EGFR-sensitive mutations (including exon 19 deletions or L858R).\n\n  9.Have not received systemic anti-tumor treatment, and are planned to receive first-line monotherapy with osimertinib, aumolertinib, or furmonertinib.\n\n  10.The main organ functions are normal, that is, they meet the following criteria:\n  1. The standard for routine blood test should meet: HB≥90 g\u002FL; ANC≥1.5×10\\^9\u002FL; PLT≥80×10\\^9\u002FL.\n  2. The biochemical examination should meet the following standards: TBIL\\\u003C1.5×ULN; ALT and AST\\\u003C2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance \\> 45 ml\u002Fmin (Cockcroft-Gault formula). 11.Women of childbearing age must have taken reliable contraceptive measures and have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and must be willing to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication. For men, they must agree to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication or have undergone surgical sterilization.\n\nExclusion Criteria:\n\n1. Subjects have received any of the following treatments:\n\n   1. Previously used any EGFR tyrosine kinase inhibitors;\n   2. Previously received any chemotherapy for lung cancer;\n   3. Previously received any radiotherapy for lung cancer (except for palliative radiotherapy for bone metastases);\n   4. Within 4 weeks before the first administration of the study medication, the subject had undergone major surgery;\n   5. Within 7 days before the first administration of the study medication, used strong inhibitors or inducers of CYP3A4.\n2. Subjects with concurrent other malignant tumors, except for basal cell carcinoma of the skin and in situ cancer.\n3. Subjects have uncontrollable malignant pleural effusion and pericardial effusion.\n4. Subjects who are allergic to contrast agents used in CT and MRI or who cannot tolerate MRI examinations.\n5. As judged by the investigator, there are any serious or poorly controlled systemic diseases, such as poorly controlled hypertension, active bleeding diathesis, or active infection.\n6. Clinically severe gastrointestinal dysfunction that may affect the intake, transport, or absorption of medication, such as the inability to take oral medication, uncontrollable nausea or vomiting, a history of extensive gastrointestinal resection, untreated recurrent diarrhea, atrophic gastritis, gastric diseases requiring long-term use of proton pump inhibitors that have not been cured, Crohn's disease, ulcerative colitis, etc.\n7. Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis.\n8. Meet any of the following cardiac examination results:\n\n   1. The average value of the corrected QT interval (QTcF) derived from three electrocardiograms (ECG) at rest using the Fridericia formula is \\> 470 msec;\n   2. Resting ECG indicates conduction or ECG morphological abnormalities (such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, and PR interval \\> 250 msec, etc.);\n   3. There are any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication of unexplained sudden death in direct relatives under 40 years old or prolonged QT interval;\n   4. The left ventricular ejection fraction (LVEF) is \\\u003C 50%.\n9. Insufficient bone marrow reserve or organ function, meeting any of the following laboratory limits:\n\n   1. Absolute neutrophil count \\\u003C1.5×10\\^9\u002FL;\n   2. Platelet count \\\u003C100×10\\^9\u002FL;\n   3. Hemoglobin \\\u003C90 g\u002FL (\\\u003C9 g\u002FdL);\n   4. If there is no clear liver metastasis, alanine aminotransferase (ALT) \\> 3 times the upper limit of normal (ULN); if there is liver metastasis, ALT \\> 5×ULN;\n   5. If there is no clear liver metastasis, aspartate aminotransferase (AST) \\> 3×ULN; if there is liver metastasis, AST \\> 5×ULN;\n   6. If there is no clear liver metastasis, total bilirubin \\> 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin \\> 3×ULN;\n   7. Creatinine \\> 1.5×ULN and creatinine clearance \\\u003C50 mL\u002Fmin (calculated by the Cockcroft-Gault formula); creatinine clearance is only required to be confirmed if creatinine \\> 1.5×ULN;\n   8. Serum albumin (ALB) \\\u003C28 g\u002FL.\n10. Active fungal, bacterial, and\u002For viral infections requiring systemic treatment.\n11. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n12. History of interstitial lung disease, drug-induced interstitial lung disease, history of radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.\n13. Subjects judged by the investigator to be likely non-compliant with the study procedures and requirements, such as those with a clear history of neurological or psychiatric disorders, or currently suffering from psychiatric disorders.\n14. Subjects judged by the investigator to have any conditions that may endanger the subject's safety or interfere with the study assessment.","75 Years",{"count":130,"type":21},100,[132],"EARLY_PHASE1","clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the cerebrospinal fluid, has better therapeutic efficacy. The main questions it aims to answer are:1.When EGFR-TKIs are sequentially combined with bevacizumab along with EGFR-TKIs for first-line treatment of advanced non-small cell lung cancer, how long can the participants survive? 2.What medical problems do participants have when using EGFR-TKIs sequentially combined with bevacizumab in conjunction with EGFR-TKIs.\n\nParticipants will:\n\nReceive EGFR-TKIs treatment for a duration of 3 months, and upon a positive cerebrospinal fluid tumor cell status, subsequently receive bevacizumab combined with EGFR-TKIs treatment until disease progression.\n\nVisit the clinic for check-ups and tests every two weeks, and have follow-up visits every six weeks after the treatment ends.\n\nKeep a record of their symptoms and disease progression.",[135,29,136],"Non Small Cell Lung Cancer","EGF-R Positive Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2024-08-13",{"date":140,"type":37},"2024-08-16",{"date":142,"type":21},"2024-08-20",{"date":144,"type":21},"2028-07-31",{"name":146,"class":44},"Second Affiliated Hospital of Nanchang University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":154,"minAge":18,"maxAge":128,"enrollmentInfo":155,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":45},"100552178","a-trial-to-evaluate-the-effect-of-applying-leukapheresis-to-enrich-ctcs-in-mpca-patients-100552178","NCT06469710","A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients","A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n1. male, aged 18-75 years; and\n2. Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration\u002Fsurgical biopsy;\n3. Good general condition, ECOG score 0-1, able to tolerate leukapheresis;\n4. Normal haematological analysis, liver and renal function tests at screening;\n5. Subjects (or their legal representatives) can understand the informed consent form.\n\nExclusion Criteria:\n\n1. those who have received systemic combination therapy for tumours within 5 years;\n2. those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections\n3. those with coagulation disorders, DIC or reduced platelets;\n4. those receiving exogenous plasma at the time of the trial;","MALE",{"count":79,"type":21},"The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are:\n\n1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment;\n2. How to obtain further information on the tumour biology of CTC;\n3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.",[158,29,159],"Prostate Cancer","Leukapheresis","2024-06-18",{"date":162,"type":37},"2024-06-24",{"date":164,"type":21},"2024-06-25",{"date":166,"type":21},"2025-12-30",{"name":70,"class":44},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":45},"100546204","phase-3-liquid-biopsy-ctdna-guided-treatment-in-localized-pancreatic-cancer-neoadjuvant-ctx-vs-upfront-surgery-100546204","NCT06391892","Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery","LIQUIPANC","Inclusion Criteria:\n\n* Informed consent\n* \\>18 years old\n* localized pancreatic cancer to go for upfront surgery\n\nExclusion Criteria:\n\n* synchronous secondary malignancy\n* pregnancy","99 Years",{"count":130,"type":21},[179],"PHASE3","This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.",[182,29,183],"Pancreatic Cancer","Predictive Cancer Model","2024-04-25",{"date":186,"type":37},"2024-04-30",{"date":188,"type":37},"2024-01-11",{"date":190,"type":21},"2026-12-31",{"name":192,"class":44},"Elisabethinen Hospital",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":200,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":217},"100540519","value-of-dynamic-monitoring-of-early-recurrence-of-hepatocellular-carcinoma-after-radical-resection-based-on-ctcs-100540519","NCT06317896","Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS","Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS: a Prospective Cohort Study","Inclusion Criteria:\n\n1. Male or female patients aged 18-75 years;\n2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 \u002Fstage A\u002Fstage B, eligible for radical surgery;\n3. ECOG physical status score is 0-1;\n4. Child-Pugh score is 5-6 points (Level A);\n5. Not received any anti-tumor therapy;\n6. Laboratory tests were at normal levels within 7 days before enrollment.\n\nExclusion Criteria:\n\n1. Patient can't provide blood samples for CTCs and CTC-DNA testing;\n2. Patient with two or more types of tumors at the same time;\n3. Non-primary liver lesions;\n4. Pregnant or lactating women;\n5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;\n6. Patient with serious heart disease;\n7. Other conditions deemed unsuitable for inclusion by the researcher.",{"count":201,"type":21},82,"On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent\u002Fmetastatic foci derived from CTCs at the molecular level in hepatocellular carcinoma, prospective clinical trials will be conducted to further validate the predictive value of the CTCS longitudinal monitoring model in predicting postoperative recurrence of hepatocellular carcinoma, and to verify whether it is earlier than imaging to indicate recurrence, to explore the clinical feasibility of CTCs in guiding postoperative adjuvant therapy of liver cancer, and to provide new ideas for early intervention strategy of liver cancer after operation, to establish a set of standardized clinical scheme of auxiliary treatment for patients with liver cancer after operation for accurate and individualized\"Early diagnosis and treatment\".",[204,29,205,206],"Hepatocellular Carcinoma","Recurrence","Surgery",[204,29,205,208],"Dynamic Monitoring","2024-03-12",{"date":211,"type":37},"2024-03-19",{"date":213,"type":21},"2024-04-01",{"date":190,"type":21},{"name":216,"class":44},"Zhujiang Hospital",3,{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":45},"100501886","phase-3-ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer-100501886","NCT05815082","ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer: A Prospective Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Both genders are eligible; aged between 18-75 years old; have received neoadjuvant chemotherapy;\n2. Patients with liver metastatic colorectal cancer who have achieved R0 resection according to MDT evaluation (including patients with metastases treated with ablation therapy that achieved similar R0 resection effects);\n3. Patients with negative ctDNA after surgery;\n4. ASA grade \\\u003CIV and\u002For ECOG performance status score ≤ 2;\n5. Have sufficient understanding of the study and voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases, including pelvic, ovarian, peritoneal, etc.;\n2. Patients with a history of other malignancies;\n3. Patients with severe liver, kidney, heart and lung dysfunction, coagulation dysfunction, or serious underlying diseases who cannot tolerate chemotherapy;\n4. Patients who are allergic to any component in the study;\n5. Patients who have received other tumor-related investigational drug therapy;\n6. Patients with severe uncontrolled recurrent infections or other serious uncontrolled concurrent diseases;\n7. Patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases that require comprehensive treatment (including mental disorders), and serious abnormal laboratory tests;\n8. Patients with a history of severe mental illness;\n9. Pregnant or lactating women;\n10. Patients with other clinical or laboratory conditions that the investigator deems unsuitable for participation in the trial.",{"count":226,"type":21},490,[179],"The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of \"watching and waiting\" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or \"watching and waiting\" treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.",[230,231,29,232],"Colorectal Cancer","Liver Metastases","Chemotherapy Effect",[230,231,234],"Circulating Tumor DNA","2023-04-14",{"date":237,"type":37},"2023-04-18",{"date":239,"type":37},"2023-02-20",{"date":241,"type":21},"2033-02-20",{"name":243,"class":44},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100500501","phase-3-postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna-100500501","NCT05797077","Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA: a Multicenter, Randomized, Controlled, Phase III Clinical Trial.","Inclusion Criteria:\n\n1. Both males and females, aged 18-75 years;\n2. Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect);\n3. Postoperative ctDNA-positive patients;\n4. ASA grade \\\u003C IV and\u002For ECOG performance status score ≤ 2;\n5. Participants must have a full understanding of the study and voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases to other sites, including the pelvis, ovaries, peritoneum, etc.\n2. Patients with a history of other malignant tumors.\n3. Patients with severe liver or kidney dysfunction, cardiorespiratory dysfunction, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy.\n4. Patients who are allergic to any component of the study.\n5. Patients who have received other tumor-related investigational drug treatments.\n6. Patients with severe uncontrolled recurrent infections or other severe uncontrolled accompanying diseases.\n7. Patients with other factors that may affect the study results or lead to early termination of the study, such as alcoholism, drug abuse, other serious diseases requiring comprehensive treatment (including mental illness), and severe laboratory abnormalities.\n8. Patients with a history of severe mental illness.\n9. Pregnant or lactating women.\n10. Patients who, in the opinion of the researchers, have other clinical or laboratory conditions that make them unsuitable for participation in the study.",{"count":252,"type":21},346,[179],"The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.",[230,231,29,256],"Cancer, Therapy-Related",[230,231,258,259],"ctDNA","maintenance therapy","2023-04-03",{"date":262,"type":37},"2023-04-04",{"date":239,"type":37},{"date":265,"type":21},"2031-02-20",{"name":243,"class":44},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":45},"100438725","phase-2-circulating-tumor-cells-and-treatment-de-escalation-after-neoadjuvant-therapy-for-her2-positive-breast-cancer-100438725","NCT04993014","Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer","Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer","HER2Cell","Inclusion Criteria:\n\n* HER2 positive breast cancer (hormone receptors positive or negative)\n* Stage I to III\n* Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab\n* Breast surgery after neoadjuvant therapy\n* Preserved coagnition\n* ECOG 0-3\n* For the randomization phase: pathological complete response (ypT0\u002FypTis and ypN0)\n* Agreement on participation and signature of de ICF\n\nExclusion Criteria:\n\n* Contradindication for trastuzumab or pertuzumab\n* Adjuvant chemotherapy. Hormone therapy is allowed\n* Second primary tumor \\\u003C 5 years, with an exception for treated non-melanoma skin cancer, and in situ cervical cancer",{"count":276,"type":21},80,[278],"PHASE2","Phase II unicentric randomized trial which will include early HER2 positive breast cancer patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab. Circulating tumor cells will be collected at neoadjuvant therapy baseline.\n\nPatients with pathological complete response will be randomized in 1:1 ratio for adjuvant trastuzumab (arm A) versus trastuzumab + pertuzumab (arm B) in a two factorial design: group A, with HER2 positive CTCs and group B, with HER2 negative\u002Fabsent CTCs.",[281,282,29],"Breast Neoplasms","HER2-positive Breast Cancer","2021-07-28",{"date":285,"type":37},"2021-08-06",{"date":287,"type":37},"2021-03-01",{"date":289,"type":21},"2028-04-30",{"name":291,"class":44},"AC Camargo Cancer Center",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":45},"100422571","eus-guided-hva-and-pva-for-circulating-tumor-dna-in-patients-100422571","NCT04782557","EUS Guided HVA and PVA for Circulating Tumor DNA in Patients","Endoscopic Ultrasound Guided Hepatic and Portal Vein Aspiration for Circulating Tumor DNA in Patients Suffering From GI Cancers","Inclusion criteria:\n\n1. Age \\>= 18 years old\n2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer\n3. Undergoing treatment with either:\n\n   1. Surgery\n   2. Neoadjuvant chemotherapy\n   3. Neoadjuvant chemoirradiation\n   4. Palliative chemotherapy\u002F immunotherapy\n\n      Exclusion criteria:\n\n   \u003C!-- -->\n\n   1. Synchronous cancer of other sites\n   2. Cardia, high lesser curve tumors, oesophagogastric junction tumors\n   3. Presence of bulky lymph nodes at lesser curve\u002F coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein\n   4. Patients with coagulopathy (international normalized ratio \\>1.3, partial thromboplastin time greater than twice that of control), platelet count \\\u003C50,000x103\u002FuL\n   5. Patients unwilling to undergo follow-up assessments\n   6. Patients with liver cirrhosis, portal hypertension and\u002F or gastric varices\n   7. Patient refusal to participate\n\n      \\-",{"count":300,"type":21},60,[24],"The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive \"liquid biopsy\" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.",[29,304],"Gastrointestinal Cancer",[29,304,306],"Endoscopic ultrasound portal vein aspiration",{"date":308,"type":37},"2021-03-04",{"date":310,"type":37},"2021-01-01",{"date":190,"type":21},{"name":313,"class":44},"Chinese University of Hong Kong","Circulating Tumor Cell;"]